Aliases & Classifications for Chronic Tic Disorder

MalaCards integrated aliases for Chronic Tic Disorder:

Name: Chronic Tic Disorder 12 15
Chronic Motor or Vocal Tic Disorder 12 71 32
Tic Disorders 43 32
Tic Disorder 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10600
ICD9CM 34 307.22
MeSH 43 D013981
NCIt 49 C116768
ICD10 32 F95 F95.1
UMLS 71 C0008701 C0040188

Summaries for Chronic Tic Disorder

Disease Ontology : 12 A tic disorder that is characterized by single or multiple motor or phonic tics, but not both, which are present for more than a year.

MalaCards based summary : Chronic Tic Disorder, also known as chronic motor or vocal tic disorder, is related to obsessive-compulsive disorder and obsessive-compulsive personality disorder, and has symptoms including symptoms and recurrent muscle twitches (symptom). An important gene associated with Chronic Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and colon, and related phenotype is behavior/neurological.

Related Diseases for Chronic Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Chronic Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 obsessive-compulsive disorder 30.1 SLITRK1 DRD4 DRD3 DRD2 DRD1 DLGAP3
2 obsessive-compulsive personality disorder 30.1 SLITRK1 DRD3
3 early-onset schizophrenia 30.1 DRD2 DRD1
4 tardive dyskinesia 30.0 DRD3 DRD2
5 personality disorder 29.9 DRD4 DRD3 DRD2
6 conduct disorder 29.9 DRD5 DRD4 DRD2
7 oppositional defiant disorder 29.8 DRD4 DRD2 CGAS
8 trichotillomania 29.5 SLITRK1 DRD4 DRD3 DRD2 DLGAP3
9 separation anxiety disorder 29.5 DRD4 CGAS
10 mood disorder 29.4 SLC18A2 DRD4 DRD3 DRD2 DRD1
11 disease of mental health 29.3 DRD5 DRD4 DRD3 DRD2 DRD1
12 attention deficit-hyperactivity disorder 29.3 SLC18A2 IMMP2L DRD5 DRD4 DRD3 DRD2
13 tic disorder 29.2 SLITRK1 SLC18A2 IMMP2L DRD5 DRD4 DRD3
14 substance abuse 29.2 DRD5 DRD4 DRD3 DRD2 DRD1
15 restless legs syndrome 29.2 DRD5 DRD4 DRD3 DRD2 DRD1
16 choreatic disease 29.1 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
17 autism spectrum disorder 29.1 IMMP2L DRD5 DRD4 DRD3 DRD2 DRD1
18 migraine with or without aura 1 29.1 DRD5 DRD4 DRD3 DRD2 DRD1
19 autism 29.1 IMMP2L DRD5 DRD4 DRD3 DRD2 DRD1
20 dystonia 29.0 SLC18A2 DRD5 DRD3 DRD2 DRD1
21 gilles de la tourette syndrome 28.9 SLITRK1 SLC18A2 IMMP2L DRD5 DRD4 DRD3
22 movement disease 28.7 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
23 psychotic disorder 28.7 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
24 impulse control disorder 28.6 SLITRK1 DRD5 DRD4 DRD3 DRD2 DRD1
25 pervasive developmental disorder 28.5 IMMP2L DRD5 DRD4 DRD3 DRD2 DRD1
26 bipolar disorder 28.5 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
27 schizophrenia 28.5 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
28 transient tic disorder 12.8
29 pediatric acute-onset neuropsychiatric syndrome 11.4
30 telogen effluvium 10.3 SLITRK1 DLGAP3
31 loose anagen hair syndrome 10.3 SLITRK1 DLGAP3
32 pyromania 10.3 SLITRK1 DRD2
33 learning disability 10.2
34 intermittent explosive disorder 10.2 SLITRK1 DRD2
35 polysubstance abuse 10.2 DRD3 DRD2
36 body dysmorphic disorder 10.2 SLITRK1 DLGAP3
37 anxiety 10.2
38 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
39 chorea, childhood-onset, with psychomotor retardation 10.2
40 cannabis abuse 10.2 DRD4 DRD2
41 tremor 10.1
42 schizotypal personality disorder 10.1 DRD4 DRD2
43 sexual disorder 10.1 DRD4 DRD3 DRD2
44 heroin dependence 10.1 DRD4 DRD2 DRD1
45 social phobia 10.1
46 streptococcal group a invasive disease 10.1
47 encephalopathy 10.1
48 schizoaffective disorder 10.0 DRD4 DRD3 DRD2
49 neuroleptic malignant syndrome 10.0 DRD3 DRD2 DRD1
50 striatonigral degeneration 10.0 DRD2 DRD1

Graphical network of the top 20 diseases related to Chronic Tic Disorder:



Diseases related to Chronic Tic Disorder

Symptoms & Phenotypes for Chronic Tic Disorder

UMLS symptoms related to Chronic Tic Disorder:


symptoms, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Chronic Tic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.28 CGAS DLGAP3 DRD1 DRD2 DRD3 DRD4

Drugs & Therapeutics for Chronic Tic Disorder

Drugs for Chronic Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Levetiracetam Approved Phase 4 102767-28-2 441341
6
Clonidine Approved Phase 4 4205-90-7 2803
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Galantamine Approved Phase 4 357-70-0 9651
9 Dopamine Agents Phase 4
10 Dopamine agonists Phase 4
11 Dopamine Antagonists Phase 4
12 Antidepressive Agents Phase 4
13 Serotonin Receptor Agonists Phase 4
14 Serotonin 5-HT1 Receptor Agonists Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Antihypertensive Agents Phase 4
17 Adrenergic Agents Phase 4
18 Adrenergic Agonists Phase 4
19 Analgesics Phase 4
20 Sympatholytics Phase 4
21 Anticonvulsants Phase 4
22 Psychotropic Drugs Phase 4
23 Antipsychotic Agents Phase 4
24 Dermatologic Agents Phase 4
25 Anti-Anxiety Agents Phase 4
26 Antiemetics Phase 4
27 Gastrointestinal Agents Phase 4
28 Neurotransmitter Agents Phase 4
29 Cholinesterase Inhibitors Phase 4
30 Cholinergic Agents Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
32
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
33 Nabiximols Investigational Phase 3 56575-23-6
34 Tiapride Hydrochloride Phase 3
35 Antibodies Phase 3
36 Immunologic Factors Phase 3
37 Immunoglobulins, Intravenous Phase 3
38 Rho(D) Immune Globulin Phase 3
39 gamma-Globulins Phase 3
40 Immunoglobulins Phase 3
41 Epidiolex Phase 3
42
Penicillin G Approved, Vet_approved Phase 2 61-33-6 5904
43
Sertraline Approved Phase 2 79617-96-2 68617
44
Azithromycin Approved Phase 2 83905-01-5 447043 55185
45
Cycloserine Approved Phase 2 68-41-7 401 6234
46
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
47 Anti-Bacterial Agents Phase 2
48 Antibiotics, Antitubercular Phase 2
49 Penicillin G Benzathine Phase 2
50 Penicillin G Procaine Phase 2

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
2 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
3 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
4 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
6 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
7 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
8 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
9 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
11 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
12 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
13 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
14 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
15 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
16 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Completed NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
17 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Recruiting NCT03087201 Phase 3 nabiximols;placebo
18 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
19 The Use of D-Cycloserine to Augment Intensive Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder Unknown status NCT01687140 Phase 2 D-Cycloserine;Placebo
20 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
21 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
22 A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder Completed NCT03625453 Phase 2 ABX-1431;Placebo
23 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
24 Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
25 A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
26 An Exploratory Study of Transcranial Magnetic Stimulation (TMS) Based on Functional Magnetic Resonance Imaging (fMRI) in the Treatment of Tic Disorder Recruiting NCT04128397 Phase 1, Phase 2
27 Efficacy and Safety of Selective Microbiota Transplantation for Tourette's Syndrome Recruiting NCT03764748 Phase 1, Phase 2 mini-FMT
28 A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder Recruiting NCT03564132 Phase 2 Yigansan;Placebo
29 A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder Completed NCT03058562 Phase 1 ABX-1431;Placebo Comparator;ABX-1431
30 Developing Effective Response Inhibition Training for Symptom Relief in Tourette Syndrome Completed NCT01440023 Phase 1
31 The Effects of Ondansetron on Brain Function Completed NCT02460341 Phase 1 ondansetron;placebo
32 Open-Trial of EPI-743 for Adults With Tourette Syndrome Completed NCT01719523 Phase 1 EPI-743
33 FAAH Inhibitor Trial for Adults With Tourette Syndrome Terminated NCT02134080 Phase 1 PF-04457845;Placebo
34 Multicentre, Randomised, Double-blinded, Placebo-controlled Trial of Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus Unknown status NCT01860300 Amoxicillin-Potassium Clavulanate Combination;placebo
35 Within Subject Design on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents With Tics Unknown status NCT02190383
36 Within Subject Design on the Efficacy of a Resources Activation Treatment Programme in Children and Adolescents With Tics Unknown status NCT02190370
37 Randomized Control Trial on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents - a Comparison With Resource Activation Treatment Unknown status NCT02144870
38 Behavioural and Neurofunctional Correlates of the Sense of Agency Unknown status NCT03361332
39 Tel Aviv Sourasky Medical Center Unknown status NCT02407951
40 An Open Label, One Arm Pilot Study to Measure the Efficacy and Safety of Dysport in the Treatment of Vocal Tics in Patients With Tourette's Syndrome and Chronic Tic Disorders Unknown status NCT02187679 Abobotulinum toxin A
41 Pilot Feasibility Trial of Positive Family Interaction Therapy Unknown status NCT01409642
42 Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder: A Feasibility Study Completed NCT02864589
43 Brain Activation in Motor and Vocal Tics in Patients With Tourette's Syndrome or Chronic Motor or Vocal Tic Disorder Using Blood Oxygenation Level Dependent Functional MRI Completed NCT00026000
44 TRECC: Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders Completed NCT00675675
45 Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder Using EEG and Surface EMG Completed NCT00081419
46 A Naturalistic Study Investigating Sleep and Cognitive Learning in Children With and Without Tic Disorders Completed NCT02676492
47 Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics Completed NCT02413216
48 Psychosocial Intervention for Young Children With Chronic Tics Completed NCT03042507
49 Online Mindfulness-based Tic Reduction: Development and Testing (Phase One) Completed NCT03525626
50 Enhancing Physical Activity in Children With Tics and Tourette Syndrome: Impact on Tic Severity and Quality of Life Completed NCT02153463

Search NIH Clinical Center for Chronic Tic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clonazepam

Cochrane evidence based reviews: tic disorders

Genetic Tests for Chronic Tic Disorder

Anatomical Context for Chronic Tic Disorder

MalaCards organs/tissues related to Chronic Tic Disorder:

40
Brain, Testes, Colon, Eye, Whole Blood, B Cells, Caudate Nucleus

Publications for Chronic Tic Disorder

Articles related to Chronic Tic Disorder:

(show top 50) (show all 168)
# Title Authors PMID Year
1
Deep slow nasal respiration with tight lip closure for immediate attenuation of severe tics. 61
32417125 2020
2
The multimodality neuroimage findings in individuals with Tourette syndrome. 61
32284198 2020
3
Effectiveness of a modified comprehensive behavioral intervention for tics for children and adolescents with tourette's syndrome: A randomized controlled trial. 61
31782167 2020
4
Heterogeneity and Polygenicity in Psychiatric Disorders: A Genome-Wide Perspective. 61
32518889 2020
5
The Premonitory Urge for Tics Scale in a large sample of children and adolescents: psychometric properties in a developmental context. An EMTICS study. 61
31802271 2019
6
The urge to blink in Tourette syndrome. 61
31525588 2019
7
Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. 61
31425826 2019
8
[Patients with tic disorders: widely known, yet underserved]. 61
31627240 2019
9
Effect of behavior therapy for Tourette's disorder on psychiatric symptoms and functioning in adults. 61
31451122 2019
10
Parental Age and Differential Estimates of Risk for Neuropsychiatric Disorders: Findings From the Danish Birth Cohort. 61
30825496 2019
11
Late-Life Tourette Syndrome Is a Cause of Unexpected Cursing in the Elderly. 61
31572160 2019
12
Progress in Pharmacological and Surgical Management of Tourette Syndrome and Other Chronic Tic Disorders. 61
31045720 2019
13
Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders. 61
30640363 2019
14
Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. 61
30540347 2019
15
Streptococcal Infections and Exacerbations in PANDAS: A Systematic Review and Meta-analysis. 61
30325890 2019
16
Therapist-guided and parent-guided internet-delivered behaviour therapy for paediatric Tourette's disorder: a pilot randomised controlled trial with long-term follow-up. 61
30772854 2019
17
Combined habit reversal training and exposure response prevention in a group setting compared to individual training: a randomized controlled clinical trial. 61
29956034 2019
18
European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. 61
29982875 2019
19
Investigating a therapist-guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents-'Online Remote Behavioural Intervention for Tics' (ORBIT) trial: protocol of an internal pilot study and single-blind randomised controlled trial. 61
30610027 2019
20
The effect of shorter exposure versus prolonged exposure on treatment outcome in Tourette syndrome and chronic tic disorders - an open trial. 61
29325470 2018
21
The neuropsychiatry of Gilles de la Tourette syndrome: The état de l'art. 61
30098800 2018
22
Association of Tourette Syndrome and Chronic Tic Disorders With Objective Indicators of Educational Attainment: A Population-Based Sibling Comparison Study. 61
29813161 2018
23
Chronic tic disorders in children with ADHD. 61
29317441 2018
24
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. 61
29944175 2018
25
Seroprevalance Anti-Toxoplasma gondii antibodies in children and adolescents with tourette syndrome/chronic motor or vocal tic disorder: A case-control study. 61
29554545 2018
26
Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. 61
28555406 2018
27
Neuroimaging Applications in Tourette's Syndrome. 61
30473198 2018
28
A Randomized Controlled Trial Comparing Behavioral, Educational, and Pharmacological Treatments in Youths With Chronic Tic Disorder or Tourette Syndrome. 61
29636706 2018
29
Olfactory functioning in adults with Tourette syndrome. 61
29874283 2018
30
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. 61
28738196 2017
31
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. 61
28574423 2017
32
Parental Psychopathology and Tourette Syndrome/Chronic Tic Disorder in Offspring: A Nationwide Case-Control Study. 61
28335873 2017
33
[Tic suppression is a new evidence-based non-farmacological treatment of chronic tic disorder]. 61
28263157 2017
34
Neurocognitive predictors of treatment response to randomized treatment in adults with tic disorders. 61
27864156 2017
35
Revisiting the co-existence of Attention-Deficit/Hyperactivity Disorder and Chronic Tic Disorder in childhood-The case of colour discrimination, sustained attention and interference control. 61
28594866 2017
36
Temporal Association of Certain Neuropsychiatric Disorders Following Vaccination of Children and Adolescents: A Pilot Case-Control Study. 61
28154539 2017
37
Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. 61
27494079 2016
38
Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review. 61
27132945 2016
39
Prenatal Maternal Smoking and Increased Risk for Tourette Syndrome and Chronic Tic Disorders. 61
27566119 2016
40
Evaluation of a cognitive psychophysiological model for management of tic disorders: an open trial. 61
26250742 2016
41
The prevalence of tic disorders for children in China: A systematic review and meta-analysis. 61
27472724 2016
42
Habit reversal training and educational group treatments for children with tourette syndrome: A preliminary randomised controlled trial. 61
27037483 2016
43
Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. 61
29388585 2016
44
Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. 61
26786936 2016
45
Relationships between Premonitory Urge and Anxiety in Youth with Chronic Tic Disorders. 61
27110050 2015
46
Validity and reliability of chronic tic disorder and obsessive-compulsive disorder diagnoses in the Swedish National Patient Register. 61
26100027 2015
47
Clinical correlates of parenting stress in children with Tourette syndrome and in typically developing children. 61
25769235 2015
48
Familial clustering of tic disorders and obsessive-compulsive disorder. 61
25692669 2015
49
Mindfulness-based stress reduction for Tourette Syndrome and Chronic Tic Disorder: a pilot study. 61
25149879 2015
50
Reward enhances tic suppression in children within months of tic disorder onset. 61
25220075 2015

Variations for Chronic Tic Disorder

Expression for Chronic Tic Disorder

Search GEO for disease gene expression data for Chronic Tic Disorder.

Pathways for Chronic Tic Disorder

GO Terms for Chronic Tic Disorder

Cellular components related to Chronic Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 SLITRK1 SLC18A2 DRD5 DRD4 DRD3 DRD2
2 integral component of plasma membrane GO:0005887 9.93 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
3 synapse GO:0045202 9.8 SLITRK1 DRD5 DRD3 DRD2 DRD1 DLGAP3
4 synaptic vesicle membrane GO:0030672 9.58 SLC18A2 DRD3 DRD2
5 ciliary membrane GO:0060170 9.54 DRD5 DRD2 DRD1
6 GABA-ergic synapse GO:0098982 9.46 SLITRK1 DRD3 DRD2 DRD1
7 9+0 non-motile cilium GO:0097731 9.43 DRD5 DRD1
8 non-motile cilium GO:0097730 9.43 DRD5 DRD2 DRD1
9 dopaminergic synapse GO:0098691 9.13 SLC18A2 DRD3 DRD2
10 glutamatergic synapse GO:0098978 9.1 SLITRK1 DRD4 DRD3 DRD2 DRD1 DLGAP3

Biological processes related to Chronic Tic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.97 DRD5 DRD3 DRD2 DRD1
2 cellular calcium ion homeostasis GO:0006874 9.87 DRD5 DRD4 DRD3
3 locomotory behavior GO:0007626 9.87 SLC18A2 DRD3 DRD2 DRD1
4 response to toxic substance GO:0009636 9.86 SLC18A2 DRD3 DRD2
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 DRD5 DRD3 DRD2 DRD1
6 synapse assembly GO:0007416 9.83 SLITRK1 DRD2 DRD1
7 visual learning GO:0008542 9.81 DRD3 DRD2 DRD1
8 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.8 DRD3 DRD2 DRD1
9 associative learning GO:0008306 9.78 DRD5 DRD2 DRD1
10 response to cocaine GO:0042220 9.78 DRD5 DRD3 DRD2 DRD1
11 negative regulation of blood pressure GO:0045776 9.77 DRD5 DRD3 DRD2
12 negative regulation of protein secretion GO:0050709 9.76 DRD4 DRD3 DRD2
13 arachidonic acid secretion GO:0050482 9.75 DRD4 DRD3 DRD2
14 regulation of dopamine secretion GO:0014059 9.72 DRD3 DRD2
15 adult behavior GO:0030534 9.72 SLITRK1 DRD2
16 behavioral fear response GO:0001662 9.72 DRD4 DRD1
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD4 DRD3 DRD2
18 response to morphine GO:0043278 9.71 DRD3 DRD2
19 adult walking behavior GO:0007628 9.71 DRD2 DRD1
20 negative regulation of adenylate cyclase activity GO:0007194 9.71 DRD3 DRD2
21 temperature homeostasis GO:0001659 9.71 DRD2 DRD1
22 transmission of nerve impulse GO:0019226 9.71 DRD5 DRD1
23 prepulse inhibition GO:0060134 9.71 DRD3 DRD2 DRD1
24 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD5 DRD3 DRD2 DRD1
25 negative regulation of cytosolic calcium ion concentration GO:0051481 9.7 DRD3 DRD2
26 long-term synaptic depression GO:0060292 9.7 DRD5 DRD1
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD3 DRD2
28 behavioral response to ethanol GO:0048149 9.7 DRD4 DRD3 DRD2
29 positive regulation of renal sodium excretion GO:0035815 9.69 DRD3 DRD2
30 grooming behavior GO:0007625 9.69 DRD2 DRD1
31 G protein-coupled receptor internalization GO:0002031 9.69 DRD3 DRD2
32 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.69 DRD5 DRD3 DRD1
33 striatum development GO:0021756 9.68 DRD2 DRD1
34 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.68 DRD4 DRD3
35 regulation of potassium ion transport GO:0043266 9.68 DRD3 DRD2
36 regulation of dopamine metabolic process GO:0042053 9.67 DRD4 DRD1
37 peristalsis GO:0030432 9.67 DRD2 DRD1
38 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD4 DRD3 DRD2
39 behavioral response to cocaine GO:0048148 9.67 DRD4 DRD3 DRD2 DRD1
40 mating behavior GO:0007617 9.66 DRD5 DRD1
41 cellular response to catecholamine stimulus GO:0071870 9.66 DRD5 DRD1
42 cerebral cortex GABAergic interneuron migration GO:0021853 9.65 DRD2 DRD1
43 dopamine transport GO:0015872 9.65 SLC18A2 DRD1
44 regulation of neurotransmitter uptake GO:0051580 9.64 DRD3 DRD2
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD3 DRD2
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.63 DRD3 DRD2 DRD1
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.62 DRD3 DRD2
48 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD4 DRD2
49 dopamine metabolic process GO:0042417 9.62 DRD4 DRD3 DRD2 DRD1
50 acid secretion GO:0046717 9.61 DRD3 DRD2

Molecular functions related to Chronic Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.8 DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.54 DRD4 DRD3 DRD2
3 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
5 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
6 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD5 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Chronic Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....